KRASG12C colorectal cancer cells have been shown to have higher basal EGFR activity compared to NSCLC cells, leading to higher phospho-ERK rebound and thus resistance to KRASG12C blockade (100). This evidence concerns the gene MAPK1 and colorectal cancer.